COST-EFFECTIVENESS

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
Isabel Carbery, Gemma Burdge, Tanya Clark, Giacomo Broglio, Dan Greer, Alaa Alakkari, Christian Philipp Selinger

BMJ Open Gastroenterology Feb 2023, 10 (1) e001105; DOI: 10.1136/bmjgast-2023-001105
Cost-effectiveness analysis of antibiotic prophylaxis versus no antibiotic prophylaxis for acute cholecystectomy
Maya Satheeskaran, Aminah Hussan, Ailin Anto, Laure de Preux

BMJ Open Gastroenterology Aug 2023, 10 (1) e001162; DOI: 10.1136/bmjgast-2023-001162
Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost–utility studies
Bhavani Shankara Bagepally, S Sajith Kumar, Meenakumari Natarajan, Akhil Sasidharan

BMJ Open Gastroenterology Jan 2022, 9 (1) e000779; DOI: 10.1136/bmjgast-2021-000779
Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis
Richard Mattock, Dhiraj Tripathi, Frank O'Neill, Joyce Craig, Jennifer Tanner, David Patch, Guruprasad Aithal

BMJ Open Gastroenterology Aug 2021, 8 (1) e000641; DOI: 10.1136/bmjgast-2021-000641
Endoscopic full-thickness resection and its treatment alternatives in difficult-to-treat lesions of the lower gastrointestinal tract: a cost-effectiveness analysis
Armin Kuellmer, Juliane Behn, Torsten Beyna, Brigitte Schumacher, Alexander Meining, Helmut Messmann, Horst Neuhaus, David Albers, Michael Birk, Andreas Probst, Martin Faehndrich, Thomas Frieling, Martin Goetz, Robert Thimme, Karel Caca, Arthur Schmidt

BMJ Open Gastroenterology Aug 2020, 7 (1) e000449; DOI: 10.1136/bmjgast-2020-000449
Cost-effectiveness of surveillance with CT colonography after resection of colorectal cancer
Karen M Kuntz, Jonah Popp, J Robert Beck, Ann G Zauber, David S Weinberg

BMJ Open Gastroenterology Sep 2020, 7 (1) e000450; DOI: 10.1136/bmjgast-2020-000450
Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes
Ryo Inada, Takeshi Nagasaka, Ayako Watanabe, Tomohiko Yagi, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Yuzo Umeda, Toshiyoshi Fujiwara

BMJ Open Gastroenterology Jul 2017, 4 (1) e000146; DOI: 10.1136/bmjgast-2017-000146
Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
M A Cozijnsen, M van Pieterson, J N Samsom, J C Escher, L de Ridder

BMJ Open Gastroenterology Dec 2016, 3 (1) e000123; DOI: 10.1136/bmjgast-2016-000123
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
Lauren Yokomizo, Berkeley Limketkai, K T Park

BMJ Open Gastroenterology May 2016, 3 (1) e000093; DOI: 10.1136/bmjgast-2016-000093

Log in using your username and password

Main menu

Log in using your username and password

You are here

COST-EFFECTIVENESS